Проблемы выбора эффективного обезболивания при мигрени
https://doi.org/10.14412/2074-2711-2023-5-109-116
Аннотация
Фармакологическая симптоматическая терапия приступов головной боли является неотъемлемой стратегией эффективного ведения пациентов с мигренью. Выбор лекарственного средства требует индивидуального подхода и учета профиля пациента, особенностей иктальных проявлений мигрени и персонального опыта купирования головной боли. В ряду рекомендованных лекарственных средств триптаны являются первой линией терапии. Фармакологические различия между триптанами позволяют выбрать наиболее эффективный препарат, основываясь на индивидуальных потребностях пациента. Учитывая приоритетное значение таких характеристик, как скорость и длительность обезболивания, постоянство эффекта при купировании последовательных приступов, выбор ризатриптана может быть оптимальным для пациентов с мигренью.
При поддержке: Статья спонсируется компанией «НоваМедика»
Об авторе
Г. Р. Табеева
Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Конфликт интересов:
Россия
Гюзяль Рафкатовна Табеева - кафедра нервных болезней и нейрохирургии.
119021, Москва, ул. Россолимо, 11, стр. 1
Конфликт интересов:
Конфликт интересов не повлиял на результаты исследования
Список литературы
1. Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi: 10.3389/fneur.2021.800605
2. Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022 Feb 1;163(2):e293e309. doi: 10.1097/j.pain.0000000000002275
3. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019 Nov;37(4):631-49. doi: 10.1016/j.ncl.2019.06.001
4. Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):37381. doi: 10.1177/0333102412438977
5. Steiner TJ, Stovner LJ, Jensen R, et al. Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0
6. Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17. doi: 10.1186/s10194-018-0846-2
7. Кирьянова ЕА, Табеева ГР. Гормональная терапия менструально-ассоциированной мигрени: за и против. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):6975. doi: 10.14412/2074-2711-2022-1-69-75
8. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202
9. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi: 10.1038/s41582-02100509-5
10. Lucas C, Geraud G, Valade D, et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache. 2006 May;46(5):715-25. doi: 10.1111/j.15264610.2006.00430.x
11. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992 Jun;152(6):1273-8. doi: 10.1001/archinte.152.6.1273
12. Lipton RB, Bigal ME, Diamond M, et al, AMPP Advisory Group: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. doi: 10.1212/01.wnl.0000252808.97649.21
13. Lipton RB, Manack AN, Serrano D, Buse DC. Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study. J Headache Pain. 2013;14(Suppl 1):P201. doi: 10.1186/1129-2377-1-S14-P201
14. Ковальчук НА, Кирьянова ЕА, Табеева ГР. Приверженность терапии пациентов с мигренью (по данным интернетопроса). Неврология, нейропсихиатрия, психосоматика. 2021;13(4):81-7. doi: 10.14412/2074-2711-2021-4-81-87
15. Мигрень. Клинические рекомендации МЗ РФ. 2021. [Migren'. Klinicheskie rekomendatsii MZ RF
16. VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69. doi: 10.1001/jama.2021.7939
17. Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidencebased guideline update: pharmacologic treat ment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20
18. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi: 10.1111/head.12499
19. Nicolas S, Nicolas D. Triptans. Treasure Island (FL): StatPearls Publishing; 2022.
20. Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs: lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12 (12):E1180. doi: 10.3390/pharmaceutics12121180
21. Табеева ГР, Амелин АВ, Ахмадеева ЛР и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133
22. Johnson B, Freitag FG. New Approaches to Shifting the Migraine Treatment Paradigm. Front Pain Res (Lausanne). 2022 Sep 6;3:873179. doi: 10.3389/fpain.2022.873179
23. Maassen Van Den Brink A, Saxena PR. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache. 2004;44(Suppl 1):S13-S19. doi: 10.1111/j.15264610.2004.04104.x
24. Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005;115(1-2):1-4. doi: 10.1016/j.pain.2005.03.008
25. Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z
26. Charleston Iv L, Burke JF. Do racial/ethnic disparities exist in recommended migraine treatments in US ambulatory care? Cephalalgia. 2018 Apr;38(5):876-82. doi: 10.1177/0333102417716933. Epub 2017 Jun 26.
27. Diamond S, Bigal ME, Silberstein S, et al. Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache. 2007 Mar;47(3):355-63. doi: 10.1111/j.15264610.2006.00631.x. Erratum in: Headache. 2007 Oct;47(9):1365.
28. Ковальчук НА, Гузий ЕА, Табеева ГР. Особенности пациентов с частой эпизодической и хронической мигренью. Доктор.Ру. 2022;21(4):13-8. doi: 10.31550/1727-2378-2022-21-4-13-18
29. Lipton RB, Munjal S, Buse DC, et al. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019 Sep;59(8):1310-23. doi: 10.1111/head.13588
30. Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013 Sep;53(8):1300-11. doi: 10.1111/head.12154. Epub 2013 Jul 23.
31. Табеева ГР, Осипова ВВ, Филатова ЕГ и др. Диагностика и лечение лекарственноиндуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4-13. doi: 10.14412/2074-27112022-1-4-13
32. Viana M, Genazzani AA, Terrazzino S, et al. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891-6. doi: 10.1177/0333102413480756
33. Ferrari A, Pinetti D, Bertolini A, et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol. 2008;64(5):489-95. doi: 10.1007/s00228-0070443-9
34. Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49(9):1258-66. doi: 10.1111/j.1526-4610.2009.01523.x
35. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001 Nov 17;358(9294):1668-75. doi: 10.1016/S0140-6736(01)06711-3
36. Cameron C, Kelly S, Hsieh SC. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi: 10.1111/head.12601
37. Block GA, Goldstein J, Polis A. On behalf of the Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache. 1998 Nov-Dec;38(10):764-71.
38. Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. doi: 10.2165/00003088200140030-00004
39. Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/1D agonists: insights into migraine pathophysiology using rizatriptan. Neurology. 2000;55(9 Suppl 2):S8-14.
40. Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs. 1999 Oct;58(4):699-723. doi: 10.2165/00003495-199958040-00013
41. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ. The anti-migraine 5HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guineapigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. doi: 10.1038/sj.bjp.0704162
42. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37-40. doi: 10.1016/s0014-2999(97)83024-5
43. Hargreaves RJ, Lines CR, Rapoport AM, et al. Ten years of rizatriptan: from development to clinical science and future directions. Headache. 2009 Feb;49 Suppl 1:S3-20. doi: 10.1111/j.1526-4610.2008.01335.x
44. Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001;21:129-36. doi: 10.1046/j.1468-2982.2001.00169.x
45. Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res. 2001;4:105-25.
46. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology. 1998 Sep;51(3):77381. doi: 10.1212/wnl.51.3.773
47. Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116
48. Rapoport AM, Tepper SJ, Sheftell FD, et al. Which triptan for which patient? Neurol Sci. 2006 May;27 Suppl 2:S123-9. doi: 10.1007/s10072-006-0586-y
49. De Boer I, Verhagen IE, Souza MNP, Ashina M. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia. 2023 Feb;43(2):3331024221143773. doi: 10.1177/03331024221143773
50. Cortelli P, Allais G, Benedetto C. Overview of Triptans in the Treatment of Acute Migraine. Eur Neurol Rev. 2017;12(2):71-7. doi: 10.17925/ENR.2017.12.02.71
51. Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A; START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin Ther. 2003 Jul;25(7):2053-69. doi: 10.1016/s0149-2918(03)80204-7
52. McMahon G. Triptans for migraine: how should triptans be used? 2010. Available from: http://blogs.nejm.org/now/index.php/ triptans-for-migraine-how-shouldtriptans-be-used/2010/07/02/ (accessed 23.02.2017).
53. Bigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007 Apr;47(4):475-9. doi: 10.1111/j.1526-4610.2007.00752.x
54. Leroux E, Buchanan A, Lombard L, et al. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. Adv Ther. 2020 Dec;37(12):4765-96. doi: 10.1007/s12325-020-01494-9
55. Olesen A, Schytz HW, Ostrowski SR, et al. Low adherence to the guideline for the acute treatment of migraine. Sci Rep. 2022 May 19;12(1):8487. doi: 10.1038/s41598-022-12545-2
56. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002 Jan;42 Suppl 1:3-9. doi: 10.1046/j.15264610.2002.0420s1003.x
57. Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep;26(9):1533-45. doi: 10.1016/j.clinthera.2004.09.011
58. Gerth WC, McCarroll KA, Santanello NC, et al. Patient satisfaction with rizatriptan vs other triptans: Direct head-to head comparisons. Int J Clin Pract. 2001 Oct;55(8):552-6.
59. Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache. 2002 Feb;42(2):93-8. doi: 10.1046/j.1526-4610.2002.02024.x
60. Хохлов АЛ, Лейкин ЗН. Сравнительное клиническое исследование фармакокинетики и биоэквивалентности препаратов ризатриптана Релонова и Максалт. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(8):1-7. doi: 10.17116/jnevro20231230811
Рецензия
Для цитирования:
Табеева ГР. Проблемы выбора эффективного обезболивания при мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(5):109-116. https://doi.org/10.14412/2074-2711-2023-5-109-116
For citation:
Tabeeva GR. Problems in the selection of effective analgesics for migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(5):109-116. (In Russ.) https://doi.org/10.14412/2074-2711-2023-5-109-116
Просмотров:
430
Послать статью по эл. почте 